Abstract
Since 1987, the GELA has initiated multicenter prospective trials for aggressive non-Hodgkin's lymphomas (NHL). Lymphoblastic lymphomas (LBL) were included in those studies until 1997, and 92 LBL patients under 61 years were identified after histological review. The protocols prescribed high-dose anthracycline regimens, four cycles given every 15 days as induction and lasted for ⩽6 months. A total of 23 patients underwent high-dose therapy consolidation followed by autologous stem-cell transplantation and 69 received standard chemotherapy regimens. Clinical characteristics showed a male predominance (66%) with a median age of 31 years, bone marrow (BM) involvement (22%), mediastinal involvement (66%) and elevated LDH (62%). At the end of treatment, it was seen that 71% of the patients achieved complete remission; four (4%) patients died during induction; 43 patients relapsed at a median time of 10 months. With a median follow-up of 34 months, the 5-year overall survival (OS) and event-free survival (EFS) rates were 32 and 22%, respectively. The only favorable factor significantly associated with survival was young age. These results are poorer than those obtained in other aggressive lymphomas treated with the same regimens and suggest that adult LBL patients should be treated with acute lymphoblastic leukemia protocols.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.
Nathwani BN, Diamond LW, Winberg CD, Kim H, Bearman RM, Glick JH et al. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer 1981; 48: 2347–2357.
Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 1981; 57: 1105–1110.
Catovsky D, Goldman JM, Okos A, Frisch B, Galton DA . T-lymphoblastic leukaemia: a distinct variant of acute leukaemia. Br Med J 1974; 2: 643–646.
Colgan JP, Andersen J, Habermann TM, Earle JD, O'Connell MJ, Neiman RS et al. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma. Leuk Lymphoma 1994; 15: 291–296.
Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992; 10: 1078–1085.
Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone AH . High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358–1365.
Milpied N, Ifrah N, Kuentz M, Maraninchi D, Colombat P, Blaise D et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989; 73: 82–87.
De Witte T, Awwad B, Boezeman J, Schattenberg A, Muus P, Raemaekers J et al. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant 1994; 14: 767–774.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M . Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860–1861.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.
Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131–1137.
Bosly A, Lepage E, Coiffier B, Fillet G, Herbrecht R, Divine M et al. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. Hematol J 2001; 2: 279–285.
Morel P, Munck J, Coiffier B, Gisselbrecht C, Lederlin P, Lavaud A, et al., for the GELA. ECVB: a new high-dose CHOP regimen followed by an intensive consolidation in patients aged <60 years with aggressive lymphoma presenting with only one adverse prognostic factor of the international prognostic index. An interim analysis of the LNH93-2 protocol on 433 patient. Blood 2610. 1997; 90(Suppl. 1).
Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.
Kaplan E, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–461.
Slater DE, Mertelsmann R, Koziner B, Higgins C, McKenzie S, Schauer P et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57–67.
Coleman CN, Picozzi Jr VJ, Cox RS, McWhirter K, Weiss LM, Cohen JR et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1628–1637.
Hoelzer D, Gökbuget N, Digel W, Faak T, Kneba T, Reutzel R et al. Leukemia GMSAAL: outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99: 4379–4385.
Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95: 416–421.
Baro J, Richard C, Sierra J, Garcia-Conde J, Garcia Larana J, Rocha E et al. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 1992; 10: 33–38.
Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F et al. Autologous vs allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690–1695.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Le Gouill, S., Lepretre, S., Brière, J. et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 17, 2220–2224 (2003). https://doi.org/10.1038/sj.leu.2403095
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403095
Keywords
This article is cited by
-
Lymphoblastic Lymphoma: a Concise Review
Current Oncology Reports (2022)
-
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma
Annals of Hematology (2020)
-
Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features
Scientific Reports (2017)
-
Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation
Annals of Hematology (2015)
-
Superior vena cava syndrome and poor performance status at presentation affect survival in mediastinal T-lymphoblastic lymphoma—a single institute experience from India
Annals of Hematology (2013)